Dogwood Therapeutics (DWTX) Competitors $4.86 +0.01 (+0.21%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$6.43 +1.57 (+32.30%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock DWTX vs. SLGL, OVID, STTK, MDCX, ENLV, KPTI, XLO, RANI, MRSN, and AKTXShould you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Sol-Gel Technologies (SLGL), Ovid Therapeutics (OVID), Shattuck Labs (STTK), Medicus Pharma (MDCX), Enlivex Therapeutics (ENLV), Karyopharm Therapeutics (KPTI), Xilio Therapeutics (XLO), Rani Therapeutics (RANI), Mersana Therapeutics (MRSN), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Dogwood Therapeutics vs. Its Competitors Sol-Gel Technologies Ovid Therapeutics Shattuck Labs Medicus Pharma Enlivex Therapeutics Karyopharm Therapeutics Xilio Therapeutics Rani Therapeutics Mersana Therapeutics Akari Therapeutics Sol-Gel Technologies (NASDAQ:SLGL) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Is SLGL or DWTX more profitable? Dogwood Therapeutics has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -107.78%. Dogwood Therapeutics' return on equity of 0.00% beat Sol-Gel Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies-107.78% -43.98% -35.28% Dogwood Therapeutics N/A N/A -34.74% Which has preferable earnings and valuation, SLGL or DWTX? Sol-Gel Technologies has higher revenue and earnings than Dogwood Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSol-Gel Technologies$11.54M3.24-$10.58M-$4.70-2.86Dogwood TherapeuticsN/AN/A-$12.35M-$18.04-0.27 Do analysts rate SLGL or DWTX? Sol-Gel Technologies presently has a consensus target price of $40.00, indicating a potential upside of 198.06%. Dogwood Therapeutics has a consensus target price of $10.00, indicating a potential upside of 105.76%. Given Sol-Gel Technologies' higher probable upside, research analysts clearly believe Sol-Gel Technologies is more favorable than Dogwood Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in SLGL or DWTX? 26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 3.9% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to SLGL or DWTX? In the previous week, Sol-Gel Technologies had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 1 mentions for Sol-Gel Technologies and 0 mentions for Dogwood Therapeutics. Sol-Gel Technologies' average media sentiment score of 0.00 equaled Dogwood Therapeutics'average media sentiment score. Company Overall Sentiment Sol-Gel Technologies Neutral Dogwood Therapeutics Neutral Which has more volatility & risk, SLGL or DWTX? Sol-Gel Technologies has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. SummarySol-Gel Technologies beats Dogwood Therapeutics on 7 of the 12 factors compared between the two stocks. Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DWTX vs. The Competition Export to ExcelMetricDogwood TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.27M$3.02B$5.51B$9.35BDividend YieldN/A2.46%4.74%4.16%P/E Ratio-0.2718.0629.1724.41Price / SalesN/A273.22435.4290.24Price / CashN/A40.5624.4827.20Price / Book-0.648.628.495.77Net Income-$12.35M-$54.98M$3.24B$264.99M7 Day Performance1.25%-0.87%0.63%-0.68%1 Month Performance0.83%16.08%7.95%7.08%1 Year PerformanceN/A14.18%30.47%23.80% Dogwood Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DWTXDogwood Therapeutics1.457 of 5 stars$4.86+0.2%$10.00+105.8%N/A$9.27MN/A-0.275Upcoming EarningsSLGLSol-Gel Technologies1.8236 of 5 stars$13.42+3.2%$40.00+198.1%+226.5%$36.22M$11.54M-2.8650Gap UpHigh Trading VolumeOVIDOvid Therapeutics4.3605 of 5 stars$0.50-0.7%$3.13+529.4%-48.3%$35.56M$570K-1.4260Upcoming EarningsSTTKShattuck Labs3.0271 of 5 stars$0.74+1.5%$7.50+909.8%-79.7%$35.06M$5.72M-0.53100Upcoming EarningsMDCXMedicus Pharma2.4164 of 5 stars$2.38-7.4%$23.50+887.4%N/A$34.88MN/A-2.05N/ANews CoverageUpcoming EarningsENLVEnlivex Therapeutics2.5222 of 5 stars$1.48+2.1%$10.00+575.7%+10.4%$34.29MN/A-2.2470Short Interest ↑Gap UpHigh Trading VolumeKPTIKaryopharm Therapeutics3.4436 of 5 stars$4.02+2.3%$37.40+830.3%-69.9%$33.96M$145.24M-0.30380XLOXilio Therapeutics3.1912 of 5 stars$0.66+1.1%$4.00+508.7%-26.6%$33.66M$6.34M-0.7870Positive NewsRANIRani Therapeutics1.9199 of 5 stars$0.55+3.7%$7.33+1,238.2%-79.5%$33.40M$1.20M-0.55110Negative NewsShort Interest ↑Gap UpMRSNMersana Therapeutics3.8748 of 5 stars$6.86+3.9%$130.00+1,795.0%-83.0%$32.90M$40.50M-0.47150Upcoming EarningsAnalyst DowngradeAKTXAkari Therapeutics2.7232 of 5 stars$1.00-0.6%$5.00+398.0%-72.7%$32.50MN/A0.009 Related Companies and Tools Related Companies SLGL Alternatives OVID Alternatives STTK Alternatives MDCX Alternatives ENLV Alternatives KPTI Alternatives XLO Alternatives RANI Alternatives MRSN Alternatives AKTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DWTX) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DWTX Stock Alerts